🇺🇸

US SEC Filing Intelligence

· daily

Significant Contract Modifications ($10M+) — September 27, 2026

The two September 2020 contract actions total $1.03B, all civilian (0% defense), with Parsons Government Services Inc. ($612M, GSA FEDSIM) and Loyal Source Government Services LLC ($421M, DHS/CBP) receiving large obligations for IT services and border medical screening, respectively. Both are neutral signals (materiality 6/10) as they are administrative modifications to existing contracts with past performance periods, not new growth awards. The dominant theme is civilian agency spending via competitive full-and-open awards, but a key risk is that both contracts lack near-term future revenue visibility: Parsons' task order ends March 2025 with negative net outlay, and Loyal Source's contract expired September 2022 with over half already outlayed. The highest-conviction signal is the absence of defense exposure in this digest, suggesting institutional investors should look elsewhere for DOD momentum. Key watch items are the recompetition of Parsons' task order and any new DHS/CBP border health solicitations.

2 total filings
· daily

Contract Deobligations Alert — September 27, 2026

This digest covers two contracts totaling $1.03 billion—both civilian awards with no defense exposure—highlighting a bifurcation in federal services spending: IT systems design via GSA and border medical screening via DHS. Parsons Corporation’s $612M cost-plus-fixed-fee delivery order is the highest-conviction signal due to materiality, though it is an administrative continuation with a finite March 2025 end date, limiting forward revenue visibility. Loyal Source’s $421M firm-fixed-price contract with CBP ended in September 2022, offering zero current revenue visibility. Key risk: the Parsons modification shows negative outlayed amounts, indicating budget reallocation rather than organic growth, while the Loyal Source contract’s completion removes near-term upside from this specific award.

2 total filings
· daily

Contract Option Exercises — September 27, 2026

The two contract option exercises total $1.03 billion in obligations, both awarded to civilian agencies (GSA and DHS) with zero defense-related content, signaling continued strength in non-defense federal IT and border security services. Parsons Corporation secured a $612M cost-plus-fixed-fee GSA FEDSIM delivery order for IT services in Washington, DC, though the negative outlayed amount and administrative continuation language suggest budget reallocation rather than organic growth. Loyal Source Government Services won a $421M firm-fixed-price DHS/CBP medical screening contract in Donna, TX, with $212M already outlayed and the performance period ended in 2022, limiting forward revenue visibility. The highest-conviction signal is the competitive, full-and-open nature of both awards, indicating these companies won on merit, but the neutral signal strength (5/10) and lack of defense exposure temper the investment thesis. Key watch items include the March 2025 end of Parsons' task order and potential recompetition, and any new DHS/CBP medical screening solicitations that could replace Loyal Source's expired contract.

2 total filings
· daily

Federal IT & Cybersecurity Contracts — September 27, 2026

The sole contract in this digest is a $612.1 million cost-plus-fixed-fee delivery order awarded to Parsons Government Services Inc. via the General Services Administration (GSA) FEDSIM, for computer systems design services in Washington, DC. This is a civilian agency contract (0/1 defense-related), reflecting the GSA's role as a central procurement vehicle for IT services. The award, made under full and open competition, signals Parsons' competitive strength in the federal IT services market, though the negative outlayed amount and administrative continuation language suggest this is a modification or extension rather than a new award, tempering the bullish signal. The contract's performance period ends in March 2025, with no option periods, creating a near-term recompetition risk. The dominant theme is the stability of civilian IT services spending, but the lack of defense exposure and the administrative nature of the modification limit the investment conviction.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 27, 2026

The September 27, 2026 mega-contract stream, totaling $1.03 billion across two civilian awards, reflects a continued federal shift toward services-based spending rather than defense hardware, with zero defense-related obligations. Parsons Corporation's $612M GSA FEDSIM cost-plus-fixed-fee delivery order for IT systems design in Washington, DC, and Loyal Source Government Services' $421M DHS/CBP firm-fixed-price medical screening award in Donna, TX, both signal robust demand for professional and labor-intensive services. The highest-conviction signal is the competitive, full-and-open nature of both awards, indicating strong execution capabilities, though the Parsons modification's negative outlayed amount and Loyal Source's completed 2022 performance period temper forward-looking revenue visibility. Key watch items include potential recompetes for both contracts and the impact of continuing resolution uncertainty on civilian agency budgets.

2 total filings
· daily

High-Value Federal Grants ($5M+) — September 27, 2026

This digest covers two civilian-agency contracts totaling $1,033,265,582, with zero defense-related obligations. The dominant theme is federal service outsourcing to support border security and IT operations, led by a $612M GSA FEDSIM award to Parsons Government Services Inc. for computer systems design and a $421M DHS/CBP award to Loyal Source Government Services LLC for medical screening. The highest-conviction signal is the Loyal Source award, which demonstrates strong competitive positioning in border-related medical services, but its completed performance period limits forward-looking revenue visibility. A key risk is the extension/modification nature of the Parsons award, which implies budget reallocation rather than new program growth, and the negative outlayed amount suggests potential scope reduction or administrative adjustments.

2 total filings
· daily

General Federal Contracts — September 27, 2026

This digest covers two large, competitively awarded civilian contracts totaling $1.03 billion, with zero defense exposure. The dominant theme is sustained federal investment in IT services and border security operations, with Parsons Corporation securing a $612M GSA FEDSIM task order for computer systems design and Loyal Source Government Services winning a $421M DHS/CBP medical screening contract. The highest-conviction signal is the neutral-to-positive competitive win for Loyal Source, but the contract's performance period ended in 2022, limiting forward revenue visibility. Key risks include the Parsons contract being a modification with a negative outlayed amount (-$64,804), suggesting budget reallocation rather than new growth, and both contracts having finite end dates with no guaranteed follow-on work.

2 total filings
· daily

New Federal Contractors — September 26, 2026

The single contract analyzed represents a $248.4M civilian award from NASA to Universities Space Research Association (USRA) for academic mission R&D services, with zero defense-related obligations. The cost-plus-fixed-fee structure provides low profit volatility but capped upside, typical of nonprofit research contracts. The highest-conviction signal is neutral, reflecting stable near-term revenue but significant renewal risk as the contract expires in November 2024. Key watch items include NASA's budget trajectory for Ames Research Center and USRA's ability to secure follow-on work, given $143.6M already outlayed.

1 total filings
· daily

Significant Contract Modifications ($10M+) — September 26, 2026

This digest covers a single, large civilian contract modification from NASA to Universities Space Research Association (USRA) valued at $248.4 million, representing the entire aggregate obligation for the period. The contract is a cost-plus-fixed-fee award for academic mission services at NASA Ames Research Center, with a neutral signal strength of 6/10 and low pricing risk. Key investment implications include stable but capped profit margins for USRA, a looming expiration date in November 2024 that creates renewal uncertainty, and partial performance with $143.6 million already outlayed. The absence of defense-related contracts and the sole civilian focus highlight NASA's sustained investment in R&D services, but the lack of follow-on awards or options beyond 2024 is a critical watch item.

1 total filings
· daily

Contract Deobligations Alert — September 26, 2026

This digest covers a single contract deobligation alert totaling $248.4 million, entirely from NASA and civilian in nature, with no defense-related awards. The dominant signal is neutral, centered on a cost-plus-fixed-fee contract to Universities Space Research Association (USRA) for academic mission services at Ames Research Center, which provides stable but capped margins and faces near-term expiration in November 2024. The highest-conviction signal is the renewal uncertainty, as $143.6 million has already been outlayed, leaving the remaining $104.8 million at risk without a follow-on award. Key risks include contract concentration on a single nonprofit entity and budget dependency on NASA's R&D allocations, while no bullish or bearish signals were identified in this period.

1 total filings
· daily

Contract Option Exercises — September 26, 2026

The sole contract in this digest is a $248.4M cost-plus-fixed-fee award from NASA Ames Research Center to the nonprofit Universities Space Research Association (USRA) for academic mission services, representing 100% civilian agency spend with no defense exposure. The contract, which began in June 2016 and ends November 30, 2024, carries a neutral signal strength of 6/10 and materiality of 5/10, reflecting stable but capped-margin revenue for USRA. The dominant theme is NASA's sustained investment in R&D services (NAICS 541712), though the contract's impending expiration creates near-term renewal uncertainty. The highest-conviction signal is the low pricing risk (cost-plus-fixed-fee) offset by the lack of options beyond 2024, making re-compete risk the key watch item. Investors should monitor NASA's FY2025 budget cycle and any follow-on award announcements for USRA's academic mission support at Ames Research Center.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 26, 2026

This digest covers a single mega contract ($100M+) from September 26, 2026, totaling $248.4M, with zero defense-related awards—entirely civilian (NASA). The dominant theme is NASA’s sustained investment in academic R&D services, led by Universities Space Research Association (USRA) under a cost-plus-fixed-fee contract. The highest-conviction signal is the contract’s impending November 2024 expiration, creating renewal uncertainty for USRA’s ~$29M annual revenue stream. Key risk: no options beyond that date, with $143.6M already outlayed, signaling partial performance and potential revenue gap.

1 total filings
· daily

High-Value Federal Grants ($5M+) — September 26, 2026

This digest covers a single high-value civilian grant of $248.4M from NASA to Universities Space Research Association (USRA) for academic mission services, with no defense-related contracts. The contract is cost-plus-fixed-fee, indicating low profit volatility but capped upside, and it expires in November 2024, posing renewal uncertainty. The highest-conviction signal is neutral, reflecting stable near-term revenue for USRA but limited growth catalyst. Key risk is the impending expiration without clear follow-on awards, while the civilian R&D sector remains stable under NASA budget trends.

1 total filings
· daily

General Federal Contracts — September 26, 2026

This digest covers a single $248.4M civilian contract awarded to Universities Space Research Association (USRA) by NASA Ames Research Center, with no defense-related exposure. The cost-plus-fixed-fee pricing structure provides stable but capped margins (6-10%), and the contract's impending expiration on November 30, 2024 introduces material renewal risk. The dominant theme is NASA's continued investment in academic R&D services, but the lack of follow-on awards or options creates a near-term revenue cliff for USRA. Key watch items include NASA's budget trajectory for academic mission support and any re-compete announcements before the contract end date.

1 total filings
· daily

All NASA Contracts — September 26, 2026

The sole contract in this digest is a $248.4M cost-plus-fixed-fee award from NASA to Universities Space Research Association (USRA) for academic mission services at Ames Research Center. As a civilian agency contract with no defense linkage, it reflects stable NASA R&D investment but carries renewal risk due to its November 2024 expiration. The neutral signal and low pricing risk suggest predictable but capped profit margins for USRA, with $143.6M already outlayed. Key watch items include the upcoming re-compete decision and NASA's budget trajectory for academic mission support.

1 total filings
· daily

Biotech Small-Cap Approvals — September 25, 2026

The September 25, 2026 approval period delivered zero NMEs, zero biosimilars, and zero label expansions, yielding three neutral 'Other' approvals classified as FALLBACK. All three approvals—DEFLAZACORT (Hikma), LANREOTIDE ACETATE (Amneal), and ROCURONIUM BROMIDE (Baxter Healthcare)—are generic or biosimilar-like entries with no disclosed peak sales estimates, exclusivity, or pricing power data. No dominant therapeutic area theme emerges, as the drugs span corticosteroids, somatostatin analogs, and neuromuscular blockers. The highest-conviction signal is the absence of any NME or Breakthrough Therapy designation, indicating a low-catalyst period for small-cap biotech investors. Key watch item: the lack of commercial detail (NOT_DISCLOSED across all entries) limits actionable investment conclusions, making this a period to monitor for future label expansions or originator responses rather than trade on today's approvals.

3 total filings
· daily

Big Pharma Approvals — September 25, 2026

This digest covers a single approval from September 25, 2026: a label expansion for Merck Sharp Dohme's sotatercept-csrk (WINREVAIR), classified as a FALLBACK approval with a bullish signal. There were no NME, biosimilar, or standard label expansion approvals in this period, making this a low-volume but directionally positive event for Merck. The approval reinforces Merck's position in the pulmonary arterial hypertension (PAH) space, though the lack of disclosed commercial details (peak sales, exclusivity, pricing power) limits conviction. The key risk is the absence of context on whether this expansion meaningfully broadens the addressable patient population or faces competitive headwinds from other PAH therapies.

1 total filings
· daily

Orphan Drug Approvals — September 25, 2026

During the single-day period of September 25, 2026, the FDA recorded only one orphan drug approval: a label expansion for Merck Sharp & Dohme’s sotatercept-csrk (Winrevair), classified as a 'fallback' type and providing a moderately bullish investment signal. No new molecular entities (NMEs), biosimilars, or additional label expansions were approved, resulting in a historically sparse approval day with zero high-value catalyst events. The sole approval does not cluster with any dominant therapeutic area theme beyond the orphan drug context, and the lack of NME activity offers no fresh pipeline breadth for the sector. Key risk remains the absence of commercial disclosure—peak sales, exclusivity status, and pricing power for this label expansion are all listed as undisclosed—limiting the depth of actionable intelligence for investors.

1 total filings
· daily

New Drug Approvals (Original) — September 25, 2026

The September 25, 2026 approval period recorded zero NMEs, zero biosimilars, and zero label expansions, with all three approvals classified as 'Other' (generic/biosimilar-like entries under FALLBACK designations). The period lacks a dominant therapeutic area theme, as the three approvals—DEFLAZACORT (Hikma), LANREOTIDE ACETATE (Amneal), and ROCURONIUM BROMIDE (Baxter Healthcare)—span distinct markets (corticosteroid, somatostatin analog, neuromuscular blocker). There is no highest-conviction bullish or bearish signal; all three carry neutral signals with moderate strength and materiality. The key watch item is the absence of NME approvals, which signals a quiet catalyst period for innovative biotech sponsors, though the generic/biosimilar entries may pressure originator pricing in niche markets.

3 total filings
· daily

VA Healthcare & Services Contracts — September 25, 2026

The digest covers a single, massive $1.2B civilian healthcare contract awarded by the Department of Veterans Affairs (VA) to TriWest Healthcare Alliance Corp on September 23, 2026. This is a non-defense award, representing a significant VA commitment to healthcare services. The contract carries a bullish signal with high materiality, but the lack of pricing details, competition context, and revenue estimates introduces execution and budget risks. The dominant theme is VA healthcare outsourcing, with TriWest as the sole beneficiary in this period.

1 total filings